Combing as a fully synthetic triglyceride - trioctanate (for injection) application

As a kind of fully synthetic triglyceride, it is suitable for the preparation of polycystic liposomes. It is the unique accessory material choice of DEPOFOAM technology. In this article, AVT Xiaobiao will introduce triglyceride (for injection) in the form of video guide.

1, Chinese name: trioctylyceryl ester (for injection)
2，Tricaprylin, Octanoic acid, 1,2,3-propanetriyl ester, glycerin tricaprylate
3, chemical name: capric acid -1, 2, 3-glycerol ester
4. Molecular formula: C27H50O6
5. CAS No. 538-23-8
6. Molecular weight: 470.68
7. Grade: medicinal injection grade
8. Record registration number :F20180000840
9. DMF record number: 022815
10. EINECS login number: 208-686-5
11, properties: clear light yellow oily liquid, soluble in most organic solvents such as ethanol, insoluble in water.
12, preservation: shading, sealing, frozen transportation and preservation, avoid storage together with strong oxidizing substances.

13. The application is as follows:

1. Triocylglyceride for Depocyt®

Cytarabine liposome, developed by Skypharm Inc., was marketed in the United States in 1999 for the treatment of Liu meningitis. Incorporating cytarabine packs into liposomes reduced the number of dressings from once every two days to once every two weeks, and significantly improved patient compliance. The phospholipids of Chu formula were composed of DOPC, DPPG, cholesterol and glycerol trioleate. The product was a 5mL saline suspension, each containing 50mg cytarabine, 28.5mGDOPC, 5mGDPPG, and 22mg cholesterol.

2. Triocylglyceride for use in DEPODUR ®

Ka Sulphate liposomes, developed by Skypharm Inc., were approved by the FDA in 2004 for preoperative anesthesia or intraoperative analgesia. The phospholipids of Chu formula were composed of DOPC, DPPG, cholesterol, triocylglyceride and trioleate. Each product contains 10mg/mL Ka sulfate, 4.2mg/mL DOPC, 0.9mg/mL DPPG, 0.3mg/mL Trioctanate, 3.3mg/mL Cholesterol and 0.1mg/mL Trioleate.

3. Triocylglyceride is applied to EXParel ®

Pacira Pharmaceuticals, Inc. 's bupivacaine liposome was approved by the U.S. Food and Drug Administration in 2011 for use in postoperative analgesia at surgical sites. The liposome extends drug release up to 72 hours. Chu uses DEPC, a new PC-based phospholipid excipient, which is the only commercially available product based on DepofoamTM technology. The phospholipids of Chu formula consist of DEPC, DPPG, cholesterol and trioctylyceride. Each bottle contained bupivacaine 13.3mg/mL, DEPC 8.2mg/mL, DPPG 0.9mg/mL, cholesterol 4.7mg/mL, and trioctylyceride 2.0mg/mL. The market and sales of EXParel ® have grown rapidly in recent years, with total sales reaching $240 million in 2015 and still rising.

Since 2007, Aweitol (Shanghai) Pharmaceutical Technology Co., Ltd has been focusing on pharmaceutical excipients as its main business direction. Focus on liposomes, fat milk based injection field; The "university + research institute + pharmaceutical enterprise" expansion mode has covered all relevant enterprises in China. Please call 400-6262-623 for more information.